Document is current
Any future updates will be listed below
-
Authors
Trainor, Patrick J.
Singh, Purnima
Wang, Xuexia
Sharafeldin, Noha
Zhou, Liting
Hageman, Lindsey
Armenian, Saro H.
Ginsberg, Jill P.
Hawkins, Douglas S.
Keller, Frank G.
Hudson, Melissa M.
Neglia, Joseph P.
Landier, Wendy
Bhatia, Smita
-
Funding
Funding for this research was provided by:
National Cancer Institute (U10CA180886, R35CA220502)
V Foundation (DT2019-010)
Children’s Oncology Group (COG-ALTE03N1)
St. Baldrick’s Foundation
Leukemia and Lymphoma Society (6563-19)
- License Information
-
More Information
Article History
Received: 2 April 2025
Accepted: 10 September 2025
First Online: 6 October 2025
Declarations
:
: Study participants were drawn from a Children’s Oncology Group study COG-ALTE03N1 (NCT00082745), a matched case-control study focused on understanding the pathogenesis of anthracycline-induced cardiomyopathy after childhood cancer. COG member institutions enrolled patients after obtaining approval from local Institutional Review Boards. Written informed consent or assent was obtained from patients, parents, or legal guardians. Cases and control subjects were identified from individuals diagnosed with cancer at ≤ 21 years of age.
: The authors declare that they have no competing interests or relationships relevant to the contents of this paper to disclose. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
